Residency · Residency · Infectiousdisease

Tuberculosis - Diagnosis and Treatment

Epidemiology

Global Burden

Tuberculosis remains the leading infectious disease killer globally, with approximately 10.6 million new cases and 1.3 million deaths occurring annually according to the World Health Organization's 2022 data. Only during the COVID-19 pandemic years was TB temporarily displaced from its position as the top infectious cause of death. The highest burden of disease is concentrated in India, Indonesia, China, the Philippines, Pakistan, Nigeria, and Bangladesh, which together account for the majority of the global caseload. Drug-resistant TB represents a formidable parallel crisis, with approximately 450,000 new cases of multidrug-resistant or rifampin-resistant TB diagnosed each year, straining treatment infrastructure and threatening the gains achieved through conventional therapeutic programs.

US Epidemiology

In the United States, approximately 8,300 tuberculosis cases were reported in 2022, yielding an incidence rate of 2.5 per 100,000 population, a figure that has been increasing following a transient decline during the COVID-19 era. Foreign-born persons account for approximately 70 percent of US TB cases, with the highest rates observed among individuals originating from Mexico, the Philippines, India, Vietnam, and China. An estimated 13 million people in the United States harbor latent TB infection, representing a vast reservoir from which future active disease may emerge. Key risk groups for TB in the US include foreign-born individuals, those with HIV co-infection, persons experiencing homelessness, incarcerated populations, healthcare workers, close contacts of active TB cases, and individuals with various forms of immunosuppression.

Pathogenesis

Natural History

The pathogenesis of tuberculosis begins with the inhalation of Mycobacterium tuberculosis organisms, with as few as one to five bacilli sufficient to establish infection. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages but possess the remarkable capacity for intracellular survival, evading phagolysosomal killing and replicating within the macrophage. The host immune response, mediated principally by CD4-positive T cells and macrophage activation, leads to granuloma formation as the hallmark of containment.

Latent TB infection represents successful immune containment of the organism, during which the patient has no symptoms, is not infectious to others, and carries a 5 to 10 percent lifetime risk of progressing to active disease, with approximately 50 percent of that risk concentrated in the first two years following initial infection. Active TB develops when immune containment fails, resulting in caseating granulomas, cavitation of pulmonary parenchyma, and potential dissemination to extrapulmonary sites. The groups at highest risk for reactivation include persons with HIV, in whom the annual reactivation risk is 5 to 15 percent, those receiving TNF-alpha inhibitors, solid organ transplant recipients, and patients with silicosis, diabetes mellitus, renal failure, or malignancy.

Diagnosis of Latent TB Infection

Testing Methods

The tuberculin skin test, also known as the TST or PPD, involves intradermal injection of purified protein derivative and is read at 48 to 72 hours after placement. The interpretation of induration size varies according to risk category. An induration of 5 millimeters or greater is considered positive in persons with HIV, close contacts of active TB cases, individuals with chest radiographic findings consistent with old healed TB, immunosuppressed patients, and organ transplant recipients. An induration of 10 millimeters or greater is positive for foreign-born persons from high-prevalence countries, injection drug users, healthcare workers, homeless and incarcerated individuals, and those with diabetes, chronic renal failure, or silicosis. An induration of 15 millimeters or greater is the threshold for persons with no known risk factors. The TST is susceptible to false-positive results from BCG vaccination, particularly when administered after infancy, and from NTM infection, as well as false-negative results from anergy associated with HIV, malnutrition, and other forms of immunosuppression, from recent infection within the first eight weeks before T-cell sensitization has developed, and from overwhelming active TB disease.

Interferon-gamma release assays, including the QuantiFERON-TB Gold Plus and T-SPOT.TB, measure the release of interferon-gamma by T cells stimulated with TB-specific antigens, specifically ESAT-6 and CFP-10. The advantages of IGRAs include the need for only a single visit, lack of interference from prior BCG vaccination, and greater specificity compared to the TST. Their disadvantages include higher cost, the requirement for laboratory processing, and the occurrence of indeterminate results in immunosuppressed patients. IGRAs are preferred over the TST in BCG-vaccinated populations.

LTBI Treatment

The ATS/CDC/IDSA 2020 guidelines have established short-course regimens as the preferred approach to LTBI treatment. The 3HP regimen consists of isoniazid plus rifapentine administered weekly for 12 doses over three months and can be directly observed or self-administered, making it the overall preferred regimen. The 4R regimen of rifampin administered daily for four months is preferred for contacts of INH-resistant TB or patients with INH intolerance. The 3HR regimen of isoniazid plus rifampin daily for three months represents an additional short-course option. Among the longer regimens, 6H or 9H consisting of isoniazid daily for six or nine months remains available, with 9H being the historical standard, though its completion rates of only 50 to 69 percent represent a major limitation. The superiority of short-course therapy is demonstrated by the markedly higher completion rates achieved with 3HP, ranging from 82 to 87 percent compared to the 53 to 69 percent observed with 9H. A critical consideration for all rifamycin-containing regimens is the extensive drug interaction profile of rifampin, which is a potent CYP3A4 inducer and cannot be used with protease inhibitors or some integrase inhibitors at standard doses, warfarin, calcineurin inhibitors, azole antifungals, and numerous other medications.

Diagnosis of Active TB

Clinical Presentation

Pulmonary TB accounts for approximately 85 percent of cases and presents with a cough lasting more than two to three weeks, hemoptysis, night sweats, weight loss, and fever. Extrapulmonary TB accounts for the remaining 15 percent, with a higher proportion observed in patients with HIV, and can involve lymph nodes, which represent the most common extrapulmonary site, the pleura, bones and joints, the genitourinary tract, the meninges, and multiple organs in miliary or disseminated disease, as well as the peritoneum and pericardium. Patients with HIV and TB co-infection frequently demonstrate atypical presentations including lower lobe infiltrates, mediastinal and hilar lymphadenopathy, minimal or absent cavitation, and a higher frequency of AFB smear-negative disease.

Imaging

The classic radiographic appearance of reactivation TB consists of upper lobe infiltrates with cavitation. Miliary or disseminated TB produces a miliary pattern of diffuse 1 to 3 millimeter nodules distributed throughout both lung fields. TB pleuritis manifests as a pleural effusion with a lymphocytic exudate and adenosine deaminase levels exceeding 40 IU/L. HIV-associated TB frequently presents with lower lobe infiltrates, mediastinal lymphadenopathy, non-cavitary disease, and may demonstrate a normal chest radiograph.

Microbiologic Diagnosis

AFB smear using Ziehl-Neelsen or fluorochrome staining achieves a sensitivity of 50 to 80 percent for pulmonary specimens, and three morning sputum specimens are recommended for optimal diagnostic yield. A positive smear indicates a high bacillary burden and signifies high infectiousness. Mycobacterial culture using liquid BACTEC MGIT media remains the gold standard, with a sensitivity of 80 to 85 percent and positivity achieved in one to three weeks on liquid media compared to three to eight weeks on solid media.

Nucleic acid amplification tests have become central to the rapid diagnosis of TB. The GeneXpert MTB/RIF Ultra achieves sensitivity of 88 to 95 percent in smear-positive specimens and 63 to 77 percent in smear-negative specimens, while simultaneously detecting rifampin resistance through identification of rpoB mutations within approximately two hours, making it the WHO-endorsed first-line diagnostic test. The Hain MTBDRplus is a line probe assay that detects both isoniazid and rifampin resistance. Drug susceptibility testing can be performed using either phenotypic methods, which represent the gold standard and require two to four weeks on liquid media, or genotypic methods that provide rapid molecular detection of resistance-associated mutations.

<image>A comprehensive diagnostic algorithm for active tuberculosis. Start with "Clinical suspicion of TB (cough >2-3 weeks, risk factors, compatible imaging)." First step: "Respiratory isolation (airborne precautions) + obtain 3 morning sputum specimens for AFB smear and culture + send GeneXpert MTB/RIF Ultra." Branch based on smear results: "AFB smear positive" (high infectiousness, start RIPE immediately) and "AFB smear negative" (lower bacillary burden). For smear-negative: "GeneXpert positive → confirmed TB, start treatment" and "GeneXpert negative → consider clinical TB diagnosis if high suspicion (CT chest, bronchoscopy with BAL for smear/culture, biopsy)." Include a "Rifampin resistance detected" pathway: "Immediate referral for MDR-TB evaluation, send for extended DST, start MDR regimen." Show culture results timeline: "Positive culture at 1-3 weeks (liquid media) → phenotypic DST at 2-4 additional weeks." Use a clear diagnostic pathway format with timing indicators.</image>

Treatment of Active TB

Standard Regimen (Drug-Susceptible TB)

The standard treatment for drug-susceptible tuberculosis follows a two-phase approach. The intensive phase spans two months and consists of four drugs administered simultaneously: isoniazid, rifampin, pyrazinamide, and ethambutol, collectively known by the mnemonic RIPE. The continuation phase spans four months and consists of isoniazid and rifampin alone. The total treatment duration for drug-susceptible pulmonary TB is six months. Directly observed therapy is recommended for all patients to ensure adherence and treatment completion.

Drug Doses

Isoniazid is dosed at 5 milligrams per kilogram with a maximum of 300 milligrams daily, or 15 milligrams per kilogram with a maximum of 900 milligrams when administered thrice weekly. Rifampin is dosed at 10 milligrams per kilogram with a maximum of 600 milligrams daily. Pyrazinamide is dosed at 25 milligrams per kilogram daily, with weight-based dosing ranging from 1,000 to 2,000 milligrams depending on the patient's weight. Ethambutol is dosed at 15 to 20 milligrams per kilogram daily. Pyridoxine, or vitamin B6, at 25 to 50 milligrams daily is administered with isoniazid to prevent peripheral neuropathy.

Extended Treatment Durations

Certain forms of TB require extended treatment beyond the standard six months. TB meningitis is treated for 9 to 12 months, with a two-month intensive phase of RIPE followed by 7 to 10 months of isoniazid and rifampin continuation, and adjunctive dexamethasone is added. Bone and joint TB is treated for 6 to 9 months, with some experts extending treatment to 9 to 12 months for spinal TB with extensive disease. Miliary TB with CNS involvement requires 9 to 12 months of therapy. Cavitary pulmonary TB in which sputum cultures remain positive at two months should have treatment extended to a total of 9 months by lengthening the continuation phase to three months.

Monitoring During Treatment

Sputum AFB smear and culture should be obtained monthly until culture conversion, which occurs in most patients by two months. Failure to convert sputum cultures by two months should prompt re-evaluation of adherence, repeat drug susceptibility testing, and consideration of drug resistance. Hepatic function should be monitored at baseline with repeat testing monthly in patients with abnormal baseline liver function tests, HIV co-infection, hepatitis, alcohol use, or age greater than 35 years. Visual acuity and color vision testing should be performed at baseline and monthly during ethambutol use to detect optic neuritis. For isoniazid hepatotoxicity, the drug should be held when AST or ALT exceeds five times the upper limit of normal in the absence of symptoms, or when it exceeds three times the upper limit of normal in the presence of hepatitis symptoms, and rechallenge should be attempted after liver function tests normalize.

Drug-Resistant TB

MDR-TB (Resistant to at least INH + RIF)

Treatment of MDR-TB must be individualized based on drug susceptibility testing, with treatment durations historically ranging from 9 to 20 months. The BPaL regimen, consisting of bedaquiline, pretomanid, and linezolid, has been evaluated in the TB-PRACTECAL and ZeNix trials and represents a revolutionary advance by providing a 6 to 9 month, all-oral regimen for MDR and XDR-TB. The WHO in 2022 recommended BPaL for MDR and pre-XDR TB, establishing it as the new standard of care for drug-resistant disease with an oral, shorter, and better-tolerated approach compared to historical regimens.

Bedaquiline is a diarylquinoline that inhibits mycobacterial ATP synthase. Its principal safety concern is QTc prolongation, necessitating ECG monitoring every two weeks during the initial treatment period. Pretomanid is a nitroimidazole activated under anaerobic conditions, with hepatotoxicity as its primary adverse effect. Linezolid is dosed at 600 milligrams daily, reduced from the earlier 1,200 milligrams to decrease toxicity, but myelosuppression and peripheral neuropathy remain significant concerns, with neuropathy occurring in more than 50 percent of patients at higher doses or longer durations, requiring weekly complete blood count monitoring during the initial treatment period.

XDR-TB

Extensively drug-resistant TB is defined as MDR-TB with additional resistance to a fluoroquinolone and at least one Group A agent, which includes bedaquiline and linezolid. Treatment relies on BPaL-based regimens with modifications guided by the specific resistance profile. Cure rates for XDR-TB were historically below 50 percent but are improving with the introduction of these newer agents.

<image>A treatment regimen comparison chart showing TB treatment evolution. Three panels: Panel 1: "Standard Drug-Susceptible TB (RIPE)" showing a timeline bar: 2 months of INH+RIF+PZA+EMB (intensive phase in red) followed by 4 months of INH+RIF (continuation phase in blue), total 6 months. Panel 2: "MDR-TB Traditional" showing an 18-20 month timeline with multiple injectable and oral agents (injectable phase + oral continuation), labeled "historical approach." Panel 3: "MDR-TB BPaL (Modern)" showing a 6-9 month all-oral regimen with Bedaquiline + Pretomanid + Linezolid, labeled "WHO 2022 recommended." Include key drug monitoring requirements: ECG for bedaquiline (QTc), CBC for linezolid (myelosuppression), LFTs for all. Use a comparative timeline format with color-coded drug blocks.</image>

TB and HIV Co-infection

Key Principles

All patients diagnosed with TB should be tested for HIV, and all patients with HIV should be screened for TB. The timing of ART initiation relative to TB treatment has been established by the SAPiT and CAMELIA trials, which demonstrated that ART should be started within two weeks of initiating TB treatment in patients with CD4 counts below 50. For patients with CD4 counts above 50, ART should be initiated within eight weeks. The critical exception is TB meningitis, in which ART should be deferred two to eight weeks due to the high risk of immune reconstitution inflammatory syndrome and the evidence that early ART initiation increases mortality in this setting. IRIS, manifesting as paradoxical worsening of symptoms after ART initiation, occurs in 20 to 30 percent of co-infected patients and is managed with prednisone as demonstrated in the PredART trial, while continuing ART.

Drug Interactions with ART

The drug interactions between rifamycins and antiretroviral agents are among the most clinically important pharmacologic considerations in TB-HIV co-management. When rifampin is used with dolutegravir, the DTG dose should be increased to 50 milligrams twice daily to achieve adequate drug levels. Rifampin can be used with efavirenz at the standard 600 milligrams dose without dose adjustment. Rifampin with protease inhibitors is absolutely contraindicated, as rifampin reduces PI levels by 80 to 90 percent, rendering them ineffective. When a PI-based regimen is necessary, rifabutin should be substituted for rifampin at a dose of 150 milligrams daily with a ritonavir-boosted PI. Rifampin has no significant interaction with tenofovir alafenamide or tenofovir disoproxil fumarate.

Key Clinical Pearls

• GeneXpert MTB/RIF Ultra is the recommended initial diagnostic test for TB -- provides result within 2 hours including rifampin resistance status
• Standard TB treatment is 6 months of RIPE (2 months intensive + 4 months continuation) -- shorter regimens under investigation but 6 months remains standard
• Failure to convert sputum cultures by 2 months should prompt re-evaluation: check adherence, repeat DST, consider resistance or alternative diagnosis
• The BPaL regimen (bedaquiline + pretomanid + linezolid) has transformed MDR-TB treatment from 18-20 months injectable regimen to 6-9 months all-oral
• TB meningitis requires adjunctive dexamethasone (proven mortality benefit) and extended treatment (9-12 months)
• Always add pyridoxine (vitamin B6) with isoniazid to prevent peripheral neuropathy
• In HIV-TB co-infection, start ART within 2 weeks for CD4 <50 (but defer for TB meningitis)

References

1. Nahid P, Dorman SE, Alipanah N, et al. Official ATS/CDC/IDSA clinical practice guideline: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195.
2. Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the NTCA and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1-11.
3. Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis (TB-PRACTECAL). N Engl J Med. 2022;386(10):945-956.
4. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741-1751.
5. WHO. WHO consolidated guidelines on tuberculosis. Module 4: treatment -- drug-resistant tuberculosis treatment, 2022 update. Geneva: WHO; 2022.

Read this lecture as Markdown